Alogabat

Overview

Alogabat is a positive allosteric modulator (PAM) and agonist ( K i <100 nM) of the GABAA α5 receptor, targeting the α5β3γ2 subunit with a Ki of 8.7 nM. Alogabat increases the expression level of α5β3γ2 in oocytes (1.97-fold). GABAA has been implicated in cognitive impairment associated with central nervous system (CNS) disorders, brain cancer (including brain tumors such as medulloblastoma), and can be used in the study of mild cognitive impairment (MCI), amnestic MCI (aMCI), age-associated memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cognitive impairment associated with cancer treatment, mental retardation, Parkinson's disease (PD), autism spectrum disorder, fragile X, Rett syndrome, obsessive-compulsive behavior, and substance addiction.

Application

Products | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Depression | Products > Disease Areas > Alzheimer's Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > GABA Receptor

Product Information

• Catalog No.: HY-132806
• CAS No.: 2230009-48-8
• Molecular Formula: C21H23N5O4
• Molecular Weight: 409.44
• Purity: 99.93%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (6.11 mM); Clear solution
• Availability: In-stock

Source

Original product source